Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-11-21
2006-11-21
Le, Long V. (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007200, C435S007210, C436S063000, C436S086000, C436S089000, C436S501000, C436S518000, C530S300000, C530S350000, C530S387900
Reexamination Certificate
active
07138246
ABSTRACT:
Methods for determining whether a test agent inhibits a 17β-HSD3, the methods comprising: obtaining a recombinant host cell that expresses the 17β-HSD3; obtaining a reaction mixture comprising the 17β-HSD3, androstenedione, and the test agent; measuring the amount of testosterone in the reaction mixture by a scintillation proximity assay (SPA) using SPA beads conjugated with a testosterone-specific antibody, wherein when the amount of testosterone is lower in the presence of a test agent than in the absence of the test agent, the test agent is identified as an inhibitor of the 17β-HSD3.
REFERENCES:
patent: WO99/46279 (1999-09-01), None
patent: WO03/022835 (2003-03-01), None
Fiet et al. (Clinical Chemistry 40(12) 2296-2305, 1994).
Geissler et al., “Male Pseudohermaphroditism Caused by Mutations of Testicular 17β-Hydroxysteroid Dehydrogenase 3”, Nat. Gen., vol. 7, pp. 34-39 (1994).
Gheiler et al., “Current Concepts in Androgen Deprivation Therapy —Is There a ‘best’ Endocrine Treatment?”, World J. Urol., vol. 18, pp. 190-193 (2000).
Inano et al., “Testicular 17β-Hydroxysteroid Dehydrogenase: Molecular Properties and Reaction Mechanism”, Steroids, vol. 48, pp. 1-26 (1986).
Labrie, “At the Cutting Edge—Intracrinology”, Mol. Cell. Endocrinol. vol. 78, pp. C113-C118 (1991).
Labrie et al., “History of LHRH Agonist Combination Therapy in Prostate Cancer”, Endocr.-Relat. Cancer, vol. 3, pp. 243-278 (1996).
Liu et al., “Androgens Regulate Proliferation of Human Prostate Cancer Cells in Culture by Increasing Transforming Growth Factor-α (TGF-α) and Epidermal Growth Factor (EGF)/TGF-α Receptor” J. Clin. Endocrinol, vol. 77, pp. 1472-1478 (1993).
Luu-The et al., “Characteristics of Human Types 1, 2 and 3 17β-Hydroxysteroid Dehydrogenase Activities: Oxidation/Reduction and Inhibition”, J. Steroid Biochem. Molec. Biol., vol. 55, No. 5/6, pp. 581-587 (1995).
Maltais, R. et al., “Synthesis and Optimization of a New Family of Type 3 17β-Hydroxysteroid Dehydrogenase Inhibotors by Parallel Liquid Phase Chemistry”, J. Med. Chem., vol. 45, pp. 640-653 (2002).
Pittaway, “Inhibition of Testosterone Synthesis in the Canine Testis In Vitro”, Contraception, vol. 27, No. 4, pp. 431-436 (1983).
Simard et al., “Comparison of In Vitro Effects of the Pure Antiandrogens OH-Flutamide, Casodex and Nilutamide on Androgen-Sensitive Parameters”, J. Urol., vol. 49, pp. 580-586 (1997).
Van Weerden et al., “Effects of Low Testosterone Levels and of Adrenal Androgens on Growth of Prostate Tumor Models in Nude Mice”, J. Steroid Biochem. Mol. Biol., vol. 37, No. 6, pp. 903-907 (1990).
Gottardis Marco
Lorenzi Matthew V.
Spires Thomas
Weinmann Roberto
You Dan
Bristol--Myers Squibb Company
Cook Lisa
Golian Paul D.
Le Long V.
LandOfFree
Methods for identifying or screening for agents that... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for identifying or screening for agents that..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for identifying or screening for agents that... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3669428